Actively Recruiting
Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
Led by Tanta University · Updated on 2024-08-16
34
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.
CONDITIONS
Official Title
Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 20 to 40 years
- Diagnosed with uterine ectopic pregnancy (interstitial, cervical, or cesarean scar pregnancy)
- Gestational age less than 9 weeks
- Embryo size smaller than 10 mm
- Serum beta-human chorionic gonadotropin (beta-hCG) levels less than 10,000 mIU/mL
You will not qualify if you...
- Basal beta hCG levels less than 1500 mIU/mL
- Contraindications to methotrexate such as liver or kidney disorders and thrombocytopenia
- Diabetes mellitus
- Severe vaginal bleeding, hemodynamic changes, or hemoperitoneum
- History of cancer
- Presence of ascites
- Presence of pleural effusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527
Actively Recruiting
Research Team
M
Mai N Ageez, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here